Browsing ICR Divisions by author "Natrajan, Rachael"
Now showing items 21-38 of 38
-
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.
Khalique, S; Pettitt, SJ; Kelly, G; Tunariu, N; Natrajan, R; et al. (WILEY, 2019-11-20)Development of resistance to platinum and poly(ADP-ribose) polymerase inhibitors via secondary BRCA gene mutations that restore functional homologous recombination has been observed in a number of cancer types. Here we ... -
Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis.
Natrajan, R; Sailem, H; Mardakheh, FK; Arias Garcia, M; Tape, CJ; et al. (PUBLIC LIBRARY SCIENCE, 2016-02-16)BACKGROUND: The intra-tumor diversity of cancer cells is under intense investigation; however, little is known about the heterogeneity of the tumor microenvironment that is key to cancer progression and evolution. We aimed ... -
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; et al. (WILEY, 2018-07-20)ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ... -
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap, TA; O'Carrigan, B; Penney, MS; Lim, JS; Brown, JS; et al. (AMER SOC CLINICAL ONCOLOGY, 2020-06-22)PURPOSE: Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging ... -
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Wilkerson, PM; Dedes, KJ; Samartzis, EP; Dedes, I; Lambros, MB; et al. (IMPACT JOURNALS LLC, 2017-01-24)PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. ... -
Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment.
Stevenson, J; Barrow-McGee, R; Yu, L; Paul, A; Mansfield, D; et al. (NATURE PORTFOLIO, 2021-03-05)In breast cancer (BC), detecting low volumes of axillary lymph node (ALN) metastasis pre-operatively is difficult and novel biomarkers are needed. We recently showed that patient-derived ALNs can be sustained ex-vivo using ... -
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.
Khalique, S; Nash, S; Mansfield, D; Wampfler, J; Attygale, A; et al. (MDPI, 2021-07-30)Ovarian clear cell carcinoma (OCCC) is a rare subtype of epithelial ovarian cancer characterised by a high frequency of loss-of-function ARID1A mutations and a poor response to chemotherapy. Despite their generally low ... -
Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study.
Barrow-McGee, R; Procter, J; Owen, J; Woodman, N; Lombardelli, C; et al. (WILEY, 2020-03-01)Understanding how breast cancer (BC) grows in axillary lymph nodes (ALNs), and refining how therapies might halt that process, is clinically important. However, modelling the complex ALN microenvironment is difficult, and ... -
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Bland, P; Saville, H; Wai, PT; Curnow, L; Muirhead, G; et al. (NATURE PORTFOLIO, 2023-08-01)SF3B1 hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that SF3B1 mutant (SF3B1MUT) cells ... -
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire, SL; Leonidou, A; Wai, P; Marchiò, C; Ng, CK; et al. (WILEY, 2015-03-01)Mutations in genes encoding proteins involved in RNA splicing have been found to occur at relatively high frequencies in several tumour types including myelodysplastic syndromes, chronic lymphocytic leukaemia, uveal melanoma, ... -
Splicing dysregulation as a driver of breast cancer.
Read, A; Natrajan, R (BIOSCIENTIFICA LTD, 2018-09-01)Breast cancer is known to be a heterogeneous disease driven by a large repertoire of molecular abnormalities, which contribute to its diverse clinical behaviour. Despite the success of targeted therapy approaches for breast ... -
SWATH mass spectrometry as a tool for quantitative profiling of the matrisome.
Krasny, L; Bland, P; Kogata, N; Wai, P; Howard, BA; et al. (ELSEVIER, 2018-03-01)Proteomic analysis of extracellular matrix (ECM) and ECM-associated proteins, collectively known as the matrisome, is a challenging task due to the inherent complexity and insolubility of these proteins. Here we present ... -
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller, RE; Brough, R; Bajrami, I; Williamson, CT; McDade, S; et al. (AMER ASSOC CANCER RESEARCH, 2016-07-01)New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based ... -
Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.
Todd, JR; Ryall, KA; Vyse, S; Wong, JP; Natrajan, RC; et al. (IMPACT JOURNALS LLC, 2016-08-17)Tumour cell-extracellular matrix (ECM) interactions are fundamental for discrete steps in breast cancer progression. In particular, cancer cell adhesion to ECM proteins present in the microenvironment is critical for ... -
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer.
Barry, P; Vatsiou, A; Spiteri, I; Nichol, D; Cresswell, GD; et al. (SPRINGER, 2018-02-01)Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge ... -
Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire, SL; Peck, B; Wai, PT; Campbell, J; Barker, H; et al. (WILEY, 2016-11-01)The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations ... -
Translational genomics of ovarian clear cell carcinoma.
Khalique, S; Lord, CJ; Banerjee, S; Natrajan, R (ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2020-04-01)Ovarian clear cell carcinomas (OCCC) are rare aggressive, chemo-resistant tumours comprising approximately 13% of all epithelial ovarian cancers, which have distinct clinical and molecular features, when compared to other ... -
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures.
Morrison, E; Wai, P; Leonidou, A; Bland, P; Khalique, S; et al. (JOURNAL OF VISUALIZED EXPERIMENTS, 2016-12-26)The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery of the next generation of novel drug targets. It is becoming apparent ...